ANTIVIRAL COMPOSITION Russian patent published in 2021 - IPC A61K31/4965 A61K33/30 A61P31/14 A61P31/16 

FIELD: medicine; pharmaceuticals.

SUBSTANCE: group of inventions relates to pharmaceutical industry, specifically to a composition for relieving clinical symptoms, clinical course and/or cure of a disease caused by exposure to a virus whose genome is encoded by a single-stranded RNA strand and which uses viral RNA-dependent RNA polymerase for its replication. Pharmaceutical composition for alleviating clinical symptoms, clinical course and/or cure of the disease caused by exposure to the virus, genome of which is encoded by a single-stranded RNA suture and which uses viral RNA-dependent RNA polymerase for its replication, containing an effective amount of favipiravir and an effective amount of a zinc compound selected from zinc sulphate, zinc acetate, zinc lactate, zinc-diethyl-bis(N-4-methylthiosemicarbazone), zinc dithiocarbamate, in weight ratio of favipiravir to zinc salt of 1:1–10:1, where the effective amount of favipiravir is 50–800 mg, the effective amount of the zinc salt is 15–250 mg. Method of treating and/or preventing a disease caused by exposure to a virus whose genome is encoded by a single-stranded RNA suture and which uses viral RNA-dependent-RNA polymerase for its replication, involving administering the above pharmaceutical composition to a subject in need thereof.

EFFECT: above described composition has pronounced action to alleviate clinical symptoms, clinical course and/or cure of the disease caused by exposure to the virus, genome of which is encoded by a single-stranded RNA suture and which uses viral RNA-dependent RNA polymerase for its replication.

10 cl, 5 dwg, 4 tbl, 4 ex